Skip to main content

  • Routine use of anticoagulation after transcatheter aortic valve replacement: Initial safety outcomes from a single-center experience

    • Posted: 09/12/2018
    • Author:

      Sergey Gurevich, Brett Oestreich, Rosemary F. Kelly, Mackenzie Mbai, Stefan Bertog, Demetris Yannopoulos and Santiago Garcia

    • 2018CRM

    Abstract

    Background

    Subclinical leaflet thrombosis (SCLT) can be seen in up to 12% of patients after transcatheter aortic valve replacement (TAVR). Anticoagulation appears to prevent and reverse SCLT but concerns exist about bleeding risk.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details